RADNOR, PA — Altasciences and Certara (Nasdaq: CERT) formed a strategic partnership aimed at integrating modeling and simulation technologies into early-stage drug development programs as pharmaceutical companies seek to reduce failure rates before human trials.
The companies said the collaboration will combine Altasciences’ drug development platform with Certara’s model-informed drug development software and strategic consulting services.
The partnership is designed to help drug developers refine dosing strategies, optimize study design and improve decision-making earlier in the development process, particularly before first-in-human studies.
According to the companies, many preclinical drug candidates fail because of toxicity issues, weak pharmacokinetics, limited efficacy or difficulties translating animal study results into human outcomes.
Marie-Hélène Raigneau, chief executive officer of Altasciences, described the partnership as an effort to reduce uncertainty during critical stages of development.
“By embedding Certara’s modeling capabilities into our platform, we can further inform critical decisions earlier and with greater confidence,” Raigneau said.
The companies also pointed to evolving U.S. Food and Drug Administration guidance encouraging more adaptive and data-driven approaches to drug development.
Jon Resnick, chief executive officer of Certara, said integrating modeling and simulation directly into operational execution could improve early-stage development decisions for biotechnology companies and investors.
Certara develops software and biosimulation technologies used by pharmaceutical and biotechnology companies to model drug behavior and clinical outcomes. Altasciences provides contract research and manufacturing services supporting preclinical and clinical drug development.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.